Fidelity Investments manages money and runs brokerage accounts for individuals, while administering workplace benefits and supporting financial advisers and institutions. Its funds span active management and index investing, and its advice services range from automated portfolios to dedicated wealth managers. Customers trade through online accounts or work with advisers by phone and at investor centers, while employers use its services for retirement savings and stock plans. The business earns advisory fees and charges for selected trades, with institutional custody and clearing services alongside its consumer accounts. Fidelity was founded in 1946 and is headquartered in Boston, Massachusetts, United States.
Company Size
10,001+
Company Stage
Debt Financing
Total Funding
$247.3B
Headquarters
Boston, Massachusetts
Founded
1946
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
The global leader in press release distribution and regulatory disclosure. Public relations and investor relations professionals rely on Business Wire for broad-based and targeted market reach.
US startup Veir has raised $24.9 million in a Series A+ round. VXI Capital, Galvanize Climate Solutions, Fidelity Investments, Congruent Ventures, The Engine, and Breakthrough Energy Ventures invested. Veir develops a way to transmit electricity using high-temperature superconductors (HTS). Its platform uses evaporative cryogenic cooling. The technology lets utilities carry more power at lower voltage within a smaller right-of-way. This helps connect the lowest-cost renewable resources to the places that need them.
Financing round led by Fidelity and T. Rowe Price funds underscores vast opportunities to bring Inscripta’s technology to the broader bioeconomy.
Soufflé Therapeutics has closed an oversubscribed $135 million Series B round led by Juvia Group. New investors include TCG Crossover Management, BB Biotech, Fidelity Management & Research Company, Balyasny Asset Management, and a sovereign wealth fund. Existing backers such as Amgen Ventures, ARCH Venture Partners, and Temasek also took part. The RNA therapies company will use the money to move its three lead programs into clinical studies. They target facioscapulohumeral muscular dystrophy (FSHD), heart failure with reduced ejection fraction, and muscle and metabolic disorders. It will also advance its pipeline in other cell types and tissues. Its REMEDY (Receptor Mediated Delivery) engine delivers oligonucleotide therapies to specific cells outside the liver. "This exceptional group of investors" backs the engine's potential, said chief executive officer Amir Nashat.
Fidelity's Jurrien Timmer predicts Q3 earnings growth could reach 30% to 35% if recent quarters' typical post-reporting bounce repeats. Despite trailing earnings being up 28% and forward earnings expected to rise another 20%, the market's trailing price-to-earnings multiple has fallen 10% year-over-year. Timmer, Fidelity's Director of Global Macro, notes that investors historically don't pay top multiples for peak earnings growth. Bloomberg data shows Q2 2026 growth estimates at 34% and Q1 2026 at 29%, well above the 11% to 15% posted from Q4 2024 through Q3 2025. The S&P 500 has already reached a record high above 7,800. Schwab's Kevin Gordon warns that a single mega-cap capital expenditure miss could disrupt earnings, noting AI stocks now carry much of the index.